| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
We already reported that transplantation of rat endothelial progenitor cells (EPCs) markedly improve hepatic regeneration and promotion of fibrolysis in state of established liver fibrosis enhancing liver function and survival rate. Recently, human peripheral CD34+ cells were reported to contain a population enriched in EPCs. We investigated whether transplantation of purified human peripheral CD34+ cells could reduce established liver fibrosis and up-regulate therapeutic regeneration. The transplanted cells differentiated into vascular and sinusoidal endothelial cells, and vascular smooth muscle cells. CD34+ cell transplantation reduced liver fibrosis in a dose-dependent fashion. Expanded CD34+ cell transplantation reduced liver fibrosis. The transplantation of expanded CD34+ cells significantly up-regulated the number of Ki67-positive hepatocyte compared with the transplantation of freshly isolated CD34+ cells in a dose dependent manner.
|
